To the editor: The recent publication by Schade et al[1][1] demonstrated that the Src/Abl kinase inhibitor dasatinib (Sprycel), used for the treatment of chronic myeloid leukemia,[2][2] inhibits the function of T cells in vitro and in vivo. Dasatinib inhibition of the Src-family kinase LCK, which
No takes yet. Share an insight, caveat, or question.
Blake et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: